Database for Annotation, Visualization and Integrated Discovery 2.1
National Institute of Allergy and Infectious Disease
The Database for Annotation, Visualization and Integrated Discovery
0
DAVID Functional Annotation Table
Gene Report
Help and Manual

Right-click and select 'Save Target As' to download results Download File
glypican 3(GPC3) glypican 3(GPC3) Related Genes Homo sapiens
CHROMOSOME X,
CYTOBAND Xq26.1,
ENSEMBL_GENE_ID ENSG00000147257,
GENERIF_SUMMARY Candidate lung tumor suppressor gene which may be regulated by tobacco exposure., Mutations in GPC3 is associated with Wilm's tumor, GPC3 is upregulated in hepatocellular carcinoma and has a role in liver carcinogenesis, These findings suggest that GPC3 is a candidate lung tumor suppressor gene whose expression may be regulated by exposure to cigarette smoke and functions to modulate cellular response to exogenous damage., Overexpressed in human hepatocellular carcinoma, hence a good molecular marker., involvement in the cellular protection against mitoxantrone in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV, Although promoter methylation is likely to affect expression status of the GPC3 gene, study results suggest that deregulation of GPC3 transcriptional expression seen in neuroblastoma and Wilm's tumor involves other regulatory levels., GPC3 is apparently a novel tumor marker useful for the diagnosis of melanoma, especially in early stages of the disorder., glypican-3-induced stimulation of hepatocellular carcinoma growth does not require convertase processing, GPC3 and SPARC in combination diagnosed 47 of 75 (66.2%) melanoma patients at an early stage (0-II)., GPC3 peptides may be applicable to cancer immunotherapy for a large number of hepatocellular carcinoma patients, Data show that forced expression of glypican-3 (GPC3) reduced the growth of hepatocellular carcinoma cells, and that FGF2-mediated cell proliferation was inhibited by GPC3., Molecular data based on gene transcriptional profiles of a 3-gene set (GPC3, LYVE1, and survivin) allow a reliable diagnosis of early hepatocellular carcinoma., Both the glycosylated and unglycosylated forms of GPC3 interact with CD26 peptidase, resulting in inhibition of the enzyme., Data show that GPC3 is observed in a significant fraction of primary and corresponding recurrent ovarian carcinomas., No hot spot for GPC3 mutations or deletions in the patients with Simpson-Golabi-Behmel syndrome., GPC is detected by immunostaining in necroinflammatory lesions, therefore its use as a cancer stain should be interpreted cautiously., GPC3 may play a role in the tumorigenesis of hepatoblastoma., staining for glypican-3 is a highly sensitive and specific method capable of distinguishing HCC from other benign and malignant hepatic lesions, GPC3 seems to be a promising diagnostic marker for differentiating yolk sac tumors from ovarian clear cell carcinomas., GPC3 confers oncogenecity through the interaction between IGF-II and its receptor, and the subsequent activation of the IGF-signaling pathway., Glypican-3 appears to be a reliable markers for ovarian germ-cell tumors., Glypican-3 expression is a potential candidate marker for early detection of lung squamous cell carcinoma., GPC3 is expressed at an early stage, suggesting that GPC3 expression in thyroid cancer is an early event in developing papillary carcinoma., Report expression pattern of glypican-3 (GPC3) during human embryonic and fetal development., GPC3 is frequently expressed in noncutaneous small cell neuroendocrine carcinoma of various origins, in particular in Merkel cell carcinoma, which, in combination with CK20, The effector cells stimulated with DCs that were transfected with pEF-hGPC3 plasmid could effectively lyse GPC3 expressing HepG2 cells., GPC3 expression in HCCs did not correlate with the size, differentiation, or stage of the tumors; the presence or absence of cirrhotic background; or the underlying etiologies, Report the expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma., A patient with the Simpson-Golabi-Behmel syndrome displays a loss-of-function point mutation in GPC3 that inhibits the attachment of this proteoglycan to the cell surface., A reliable marker for the detection of hepatocellular carcinoma in liver biopsies., overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma., Our data supports the potentially significant diagnostic utility of GPC-3 in fine-needle aspiration biopsies in differentiating primary malignant from benign and preneoplastic liver lesions, and metastatic carcinomas., GPC3 expression is correlated with poor prognosis in hepatocellular carcinoma., Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis., SALL4 is a more sensitive marker than PLAP, AFP, or glypican-3 for extragonadal yolk sac tumors., Serum GPC3 is highly specific for detecting hepatocellular carcinoma (HCC). The combined use of serum GPC3 and alpha-fetoprotein may better differentiate HCC from benign liver disorders, as well as from other liver cancers., Data show that mutated GPC3 lacking the GPI anchoring domain (sGPC3) significantly inhibited the in vivo growth, blocked Wnt signaling and Erk1/2 and Akt phosphorylation in tumors., glypican-3 is involved in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma, YST can display a variety of growth patterns that can be confused with other germ cell tumour components. GPC3 detects all growth patterns tested and has a higher sensitivity for detecting YST, GPC3, in conjunction with MMPs and growth signaling molecules, might play an important role in the progression of hepatocellular carcinoma., Data demonstrate for the first time the presence of elevated levels of GPC3 protein associated with cell growth inhibition in ovarian clear cell carcinoma., Mechanism mediating the oncogenic function of SULF2 in human hepatoma that includes GPC3-mediated activation of Wnt signaling., GPC3 plays a role in glucose transport by interacting with GLUT1., Data show that glypican 3 is a sensitive and specific serum marker for diagnosis of early hepatocellular carcinoma., GPC3 may be a useful adjunct immunohistochemical marker in differentiating placental site trophoblastic tumor from non-trophoblastic tumors., loss of the functional GPC3 protein by 43% is closed to the threshold to develop the Simpson-Golabi-Behmel syndrome phenotype, Circumferential membranous GPC3 immunoreactivity in hepatocellular carcionoma indicates poorer prognosis particularly in patients with hepatitis c virus infection., Expression of GPC3 was found to be markedly elevated in HCCs. In the human HCC cell lines, GPC3 expression was consistently observed, and was mainly located in the cell membrane and cytoplasm., Study confirm the differential GPC3 expression in two human HCC cells, Hep G2 (high) and HLF (negligible)., The results confirm the high expression of GPC3 in hepatocellular carcinoma and suggest its potential diagnostic value as a clinical marker for this disease., overview of Gpc-3 expression in hepatocellular carcinoma and its expression of relationship between clinicopathological features of hepatocellular carcinoma, analysis expression of Gpc-3 in liver cell adenoma, heterosexual hyperplasia and hepatitis C, GPC3 is highly expressed in advanced hepatocellular carcinoma, moderately expressed in well-differentiated HCC, and not expressed at all in dysplastic or cirrhotic nodules, focal nodular hyperplasia and hepatocellular adenoma., The sensitivity of hepatocellular carcinoma diagnosis can be improved by combined detection of AFP and GPC3 mRNA expressions., This study highlights expression of glypican-3 in rhabdomyosarcomas but not other soft tissue sarcomas., High GPC3 mRNA expression is associated with lung squamous cell carcinoma., GPC-3 was highly expressed in hepatocellular carcinoma, moderately expressed in surrounding tissues and not expressed in distal tissues., Results suggest that GPC3 contributes to the proliferation and metastasis of hepatocellular carcinoma and that it may be a potential molecular target for HCC treatment., GPC3 might be a valuable marker closely related with prognosis and post-operative metastasis/recurrence in hepatocellular cancer patients., In a cohort analysis of disease-free survival, aberrant tumor expression of osteopontin and GPC3 were prognostic factors for recurrence and poor outcome., molecular targeting of GPC3 at the translational level offers an effective option for the clinical management of GPC3-positive HCC patients., Results show there was no correlation between GPC3 levels and prognostic parameters in hepatocellular carcinoma. GPC3 is not a useful diagnostic and prognostic marker for HCC., Our data demonstrate that GPC3 is expressed in a subset of undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver., GPC3 is a helpful ancillary diagnostic marker for pancreatic solid pseudopapillary neoplasm, results show that GPC3 is specifically overexpressed in hepatocellular carcinoma tissue and may be regarded as a potential marker for differential diagnostic hepatocellular carcinoma, Loss of glypican 3 is associated with metastasis in hepatocellular carcinoma., The results suggest that GPC3 regulates cell proliferation by enhancing the resistance to apoptosis through the dysfunction of the Bax/Bcl-2/cytochrome c/caspase-3 signaling pathway and therefore plays a critical role in the tumorigenesis of hepatocellular carcinoma., glypican 3 is strongly positive in yolk sac tumors but is not as specific a tumor marker as SALL4 for that tumor type., These findings indicate that miR-219-5p exerts tumor-suppressive effects in hepatic carcinogenesis through negative regulation of glypican 3 expression [MiR-219-5p]., Elevated levels of c-Myc correlate with the overexpression of GPC3 in human Hepatocellular Carcinoma samples., In a subgroup of hepatocellular carcinoma, the up-regulation of glypican-3 was associated with a concomitant down-regulation of its repressor miR-1271., study reveals that GPC3 promotes the growth of hepatocellular carcinoma (HCC) by increasing cell proliferation, enhancing metastasis as well as invasion; GPC3 may collaborate with YAP to regulate the HCC development, Glypican-3 can be expressed in 14% of carcinomas/neoplasms of the gastrointestinal tract and pancreas., Evaluation of GPC3 immunoexpression may be a useful diagnostic tool to distinguish epithelioid sarcomas from malignant rhabdoid tumors., results suggest that expression and activation of mitogenic receptors MET and EGFR, combined with potential mitoinhibitory effects of FAS and GPC3, create stimuli in which cell proliferation is limited and transdifferentiation process is enhanced., High glypican-3 expression is associated with hepatoma., We present a novel role for TFPI and GPC3 in regulating hematopoietic stem cell homing as well as retention in the bone marrow., Glypican 3 and arginase-1 are the most reliable markers for identifying scirrhous hepatocellular carcinoma., Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma., Data suggest that the use of monoclonal antibody (7D11 mAb) might be good for Glypican-3 (GPC3) large-scale applications for clinical diagnosis of hepatocellular carcinoma (HCC)., GPC3 positivity was limited to a small subset of central nervous system neoplasms and may thus serve as a useful positive diagnostic biomarker, GPC-3 protein/mRNA overexpression and alpha-fetoprotein levels could be used as markers for the diagnosis of HCC and monitoring its metastasis., miR-1291 is a biologically relevant regulator of GPC3 expression in hepatoma cells and acts through silencing of the endoplasmic reticulum stress sensor IRE1alpha., In order to better delineate the phenotypic spectrum of SGBS caused by GPC3 mutations, and to try to define specific clinical criteria for GPC3 molecular testing, we reviewed the clinical features of all male cases with a GPC3 mutation, We now report that human primary suture mesenchymal cells coexpress GPC1 and GPC3 on the cell surface and release them into the media, average level of sGPC3 in HCC patients was 99.94+/-267.2ng/ml, which was significantly higher than in patients with chronic hepatitis, liver cirrhosis, non-HCC cancer and healthy controls, GPC3 is comparable to AFP as a serum marker for the diagnosis of HCC, combination of AFP and GPC3 can elevate the sensitivity of diagnosis, The unique disease-causing mutation likely arose de novo in the mother. It is a deletion-insertion that leads to a frameshift at the p.S349 residue of GPC3 and a premature stop codon after five more amino acids, The usefulness of serum Transforming growth factor-beta1 (TGF-beta1), Glypican-3 (GPC3), and Golgi protein-73 (GP73) mRNAs as early biomarkers in HCC Egyptian patients, was investigated., Immunocytochemical staining for GPC3 in cell block material is a highly sensitive and specific method capable of distinguishing HCC from the vast majority of metastatic carcinomas of the liver., GPC3 expression is frequent in squamous cell carcinomas and invasive urothelial carcinomas, It is a tumor marker for diagnosis of hepatocellular carcinoma (HCC)., GPC-3 has moderate diagnostic accuracy for HCC., We show that GPC3, an hepatocellular carcinoma biomarker and Hh mediator, regulates human stellate cell viability by regulating Hh signaling., Both the GPC3 and the CTNNB1 mutations contributed to tumorigenesis., High Serum glypican-3 level is associated with hepatocellular carcinoma., Glypican-3 (GPC3) is an HSPG that is highly expressed in hepatocellular carcinoma, where it can attract Wnt proteins to the cell surface and promote cell proliferation., Data demonstrate that GPC3 plays a more direct role in the stimulation of Wnt signaling., Data suggest that glypican-3 (GPC3)-positive dysplastic nodules (DN) was really a late premalignant lesion of hepatocellular carcinoma (HCC)., in the current study we evaluated the safety, tolerability, and pharmacokinetic (PK) characteristics of GC33 ( a humanized mAb against human glypican-3)in Japanese patients., GPC3 overexpression indicates a poor prognosis for patients with HCC, and it may also have predictive potential for HCC invasion and metastasis., high expression was found for GPC-3 membrane protein in hepatocellular carcinoma, Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line., Glypican-3 is the only oncofetal antigen that showed comparable high diagnostic accuracy as PIVKA-II in diagnosing HCC among Egyptian patients., GPC3 overexpression tends to be associated with a poor prognosis (poor OS or DFS) in hepatocellular carcinoma [meta-analysis], In the title., This study identified heparan sulfate, partly through glypican-3, as a novel binding partner of GEP on the surface of liver cancer cells., Data shows that GPC3 gene expression is downregulated in primary clear cell renal cell carcinoma; its overexpression arrest cells in G1 phase suggesting its role as tumor suppressor in clear cell renal cell carcinoma., Data indicate that zinc-fingers and homeoboxes 2 (ZHX2) suppresses glypican 3 (GPC3) transcription by binding with its core promoter., GPC3 is associated with the HCC cell biological behavior., Most cases of hepatoblastoma and yolk sac tumor, and some cases of other tumors were found to express GPC3. On the other hand, GPC3 was physiologically expressed during the fetal and neoinfantile period under 1 year of age., the elevated GPC3 expression in the majority of primary and metastatic Wilms tumors, but not in other renal neoplasms, indicates a possible role of GPC3 in Wilms tumor development, GPC3 expression is an independent prognostic factor for postoperative hepatocellular carcinoma, This study demonstrated that highly expression of GPC3 could enrich hepatocellular carcinoma -related genes' mRNA expression and positive associate with dysplasia in cirrhotic livers., GPC3 contributes to hepatocellular carcinoma progression and metastasis through impacting epithelial-mesenchymal transition of cancer cells, and the effects of GPC3 are associated with ERK activation., GPC3 and E-cadherin expressions are not independent prognostic factors in CRC., propose that the structural changes generated by the lack of cleavage determine a change in the sulfation of the HS chains and that these hypersulfated chains mediate the interaction of the mutant GPC3 with Ptc, High expression of glypican-3 is associated hepatoblastoma., In HCC patients, sGPC3N levels were significantly increased (mean/median, 405.16/236.19 pg mL(-1) ) compared to healthy controls (p < 0.0001), and 60% of HCC cases (69/115) showed sGPC3N levels that were higher than the upper normal limit., Data indicate that the triple stain of reticulin, glypican-3, and glutamine synthetae is useful in the differentiation of hepatocellular carcinoma, hepatic adenoma, and focal nodular hyperplasia., OPN, SPINK1, GPC3 and KNPA2 were significantly over-expressed in HCC tissues. These genes may be useful in developing future biomarkers and therapeutic strategies for HCC, potential role of GPC3 in urothelial carcinogenesis warrants further investigation, especially the potential use of Glypican-3 for therapeutic and diagnostic purposes, Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of ovarian cancer., Identify a GPC3-specific T-cell receptor. Expression of this receptor by T cells allows them to recognize and kill GPC3-positive hepatoma cells., Review, study suggests that GPC3 is involved in HCC cell migration and motility through HS chain-mediated cooperation with the HGF/Met pathway, showing how HS targeting has potential therapeutic implications for liver cancer, GPC3 may be a candidate marker for detecting lung squamous cell carcinoma., In this meta-analysis, GPC3 was found to be acceptable as a serum marker for the diagnosis of hepatocellular carcinoma., Data show that notum and glypican-1 and glypican-3 gene expression during colorectal cancer (CRC) development and present evidence to suggest them as potential new biomarkers of CRC pathogenesis., In South Korean hepatocellular carcinoma patients, GPC3 expression was more frequent in hepatocellular carcinoma with aggressive features, but it was not an independent prognostic biomarker., GPC3 expression was measured in hepatocellular carcinoma at different stages and correlated with prognosis. CK19+/GPC3+ HCC has the highest risk of intrahepatic metastasis, microvascular invasion, regional lymph node involvement, and distant metastasis.,
OFFICIAL_GENE_SYMBOL GPC3,
OMIM_DISEASE Wilms tumor, somatic, Simpson-Golabi-Behmel syndrome, type 1,
SP_COMMENT disease:Defects in GPC3 are the cause of Simpson-Golabi-Behmel syndrome (SGBS) [MIM:312870]; also known as Simpson dysmorphia syndrome (SDYS). SGBS is a condition characterized by pre- and postnatal overgrowth (gigantism) with visceral and skeletal anomalies., function:Cell surface proteoglycan that bears heparan sulfate., function:Cell surface proteoglycan that bears heparan sulfate. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition., similarity:Belongs to the glypican family., tissue specificity:Highly expressed in lung, liver and kidney.,